论文部分内容阅读
目的:观察瑞格列奈联合罗格列酮治疗糖尿病的临床疗效。方法:选择我院60例糖尿病患者为实验对象,将其随机分成观察组和对照组,平均每组30例,观察组选用瑞格列奈联合罗格列酮治疗,对照组直接选用瑞格列奈治疗,观察并分析两组患者的治疗效果。结果:观察组的显效率为56.67%,总有效率为90%,对照组的显效率为40%,总有效率为70%,明显低于观察组,P<0.05。结论:瑞格列奈联合罗格列酮治疗糖尿病可以明显降低患者的血糖水平、提升患者的体质量指数,效果十分显著,值得在临床上推广。
Objective: To observe the clinical efficacy of repaglinide combined with rosiglitazone in the treatment of diabetes mellitus. Methods: Sixty diabetic patients in our hospital were selected as experimental subjects. They were randomly divided into observation group and control group with an average of 30 in each group. The observation group was treated with repaglinide and rosiglitazone. The control group was treated with RIGOL Chennai treatment, observation and analysis of the treatment effect of two groups of patients. Results: The markedly effective rate was 56.67% in the observation group and the total effective rate was 90%. The effective rate in the control group was 40% and the total effective rate was 70%, which was significantly lower than that in the observation group (P <0.05). Conclusion: The combination of repaglinide and rosiglitazone in the treatment of diabetes can significantly reduce the blood sugar level of patients and improve the body mass index of patients. The effect is very significant and worthy of clinical promotion.